THE POST COVID IMMUNE TEST WAS DEVELOPED BY COMBINING THREE DISTINCT TESTS THAT CAN PROVIDE A FULL PICTURE OF THE IMMUNE SYSTEM POST-COVID.

1 - ASSESSMENT OF OVERALL IMMUNOPHENOTYPE

The test looks at the composition of lymphocytes of the immune system.

  • T-Cells: Cells that can fight the virus directly.

  • B-Cells: Create antibodies.

  • NK-Cells: Preformed cells that can attack cell that the virus infects.

  • Dendritic-Cells: First type of cells that serve infection.

The test assesses absolute counts, memory phenotype of B and T-Cells, as well as maturation/activation.

Learn more about the panel HERE.

 

2 - CASPASE-1 EXPRESSION

The test looks at the Caspase-1 expression in lymphocytes and monocytes. Caspase-1 is a molecule that is part of the inflammasome that plays a role in, not only inducing immunity, but also inflammation. Caspase-1 expression is increased in more than 95% of COVID-19 infections in the acute stage during the first month of infection. It stays elevated in long-COVID (1). Patients should discuss various treatment options with their healthcare providers.

Learn more about the panel HERE.

 

3 - CPASS™  NEUTRALIZING ANTIBODY PANEL

The cPass test is faster, easier, more scalable, and readily automatable compared to the traditional neutralizing antibody tests, such as virus neutralization test (VNT), pseudo-virus neutralization test (pVNT), and plaque reduction neutralization test (PRNT).

The panel contains two key components: the Horseradish peroxidase (HRP) conjugated recombinant SARS-CoV-2 RBD fragment (HRP-RBD) and the human ACE2 receptor protein (hACE2).

The SARS-CoV-2 sVNT Kit is a blocking ELISA detection tool, which mimics the virus neutralization process. The test uses the interaction between viral protein-receptor protein to mimic the virus infection of a live cell, which is monitored by a chromogenic reaction. When there are neutralizing antibodies in the patient sera, they will block the specific protein-protein interaction and hence reducing the chromogenic reaction, mimicking the virus neutralization process.

Learn more about the panel HERE.

 

(1) Plassmeyer M, et al. Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS-CoV-2 infection and long COVID. Allergy. 2022 Jan;77(1):118-129.

Stay informed of our latest breakthroughs.